Business Wire

Indivumed Services’ Hamburg Site Receives College of American Pathologists (CAP) Accreditation

Share

Indivumed Services GmbH, a Crown Bioscience company, announced that its Hamburg site received laboratory accreditation from the College of American Pathologists (CAP). The CAP accreditation, recognized as the gold standard for laboratory quality control in the industry, is reserved for top-tier laboratories that meet and maintain the highest standards of quality, accuracy, and consistency in the testing of clinical biospecimens. This distinction places Indivumed Services among the top 10% of laboratories globally, solidifying its commitment to excellence in laboratory services.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230911457952/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Indivumed Services CAP Accreditation Mark (Graphic: Business Wire)

This achievement strengthens Indivumed Services’ global reputation in providing and analyzing clinical biospecimens, while paving the way for future Clinical Laboratory Improvement Amendments (CLIA) certification. This certification will enable the analysis of patient-derived samples across all clinical trial phases, ensuring expert end-to-end support from assay development utilizing Indivumed Services’ industry leading biobank, through to analyzing samples from downstream clinical research.

Overall, Indivumed Services’ CAP accreditation enhances its flexibility and enables the expansion of its services into new markets. This will foster stronger partnerships, ultimately benefiting both existing and new customers.

Simone Hubo, PhD, Vice President of Quality and Regulatory Affairs at Indivumed Services, stated: “With this accreditation, our customers can rest assured that the samples and analyses provided by Indivumed Services are of industry-leading quality. This means they can have confidence that the laboratory is performing at the highest global standard for quality.”

Armin Spura, PhD, Chief Executive Officer of Crown Bioscience, added: “When Crown Bioscience identified Indivumed Services as a potential acquisition, one of the key attributes that attracted us was the high quality of the operations teams and their ability to continue to support clients through the transition from preclinical to clinical development. Obtaining CAP accreditation validates this assessment and solidifies our commitment to advancing our translational research platforms so that we can provide superior options for bridging the gap between preclinical and clinical research. This achievement is a testament to the expertise of our highly qualified professionals and the cutting-edge technologies they expertly use.”

###

About Indivumed Services

Indivumed Services boasts a highly curated and characterized biobank, comprising nearly one million samples with associated clinical data. In addition, the company has established a wide-reaching network of more than 60 clinical sites spanning the United States, Europe, and Asia. This network provides direct and controlled access to surgical biospecimens, and blood samples annotated with comprehensive clinical data, all obtained in accordance with unique SOPs to standardize ischemia time, ensuring quality and suitability for multi-omics analyses and model development. Indivumed Services is a wholly owned subsidiary of Crown Bioscience and maintains operations in Germany and the United States.

For more information, please visit http://www.indivumedservices.com

About Crown Bioscience

Crown Bioscience, a JSR Life Sciences company, is a global CRO that provides preclinical and translational platforms to help our customers advance their research and development in oncology, immuno-oncology, and immune-mediated inflammatory diseases. We are the exclusive preclinical CRO to offer tumor organoid services with the well-established Hubrecht Organoid Technology. In addition, we have developed the largest commercially available PDX collection in the world. We focus on helping our customers develop novel therapies to maximize the chances that patients receive the right treatment at the right time. Founded in 2006, Crown Bioscience has 14 facilities across the United States, Europe, and Asia.

For more information, please visit www.crownbio.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Inquiries:
Crown Bioscience
Sarah Martin-Tyrrell
pr@crownbio.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SES Market Update in Context of Moody’s Ratings Press Release18.2.2025 19:10:00 EET | Press release

SES S.A. has taken note of Moody’s Ratings Press Release today with regards to SES and is providing a market update ahead of its Full Year 2024 financial results announcement on 26 February 2025. SES expects Full Year 2024 Results(1) to be better-than-expected with Revenue at the top end of the financial outlook range (€1,940-2,000 million)(2) and Adjusted EBITDA above the outlook range (€950-1,000 million)(2). The proposed acquisition of Intelsat is on track to close during H2 2025. SES expects to reconfirm all financial targets for the combined company (pre-IRIS2) published in the transaction announcement in April 2024, including low- to mid-single digit average annual growth in Revenue for 2024-2028E, mid-single digit average annual growth in Adjusted EBITDA for 2024-2028E, and strong Free Cash Flow generation. SES remains committed to maintaining Investment Grade metrics. SES management looks forward to announcing its Full Year 2024 Results and discussing these, as well as its view

Planview Acquires Sciforma, Expanding Global Leadership in Portfolio Management Solutions18.2.2025 19:00:00 EET | Press release

Planview®, the leading platform for Strategic Portfolio Management (SPM) and Digital Product Development (DPD), today announced it has completed its acquisition of Sciforma, a prominent provider of Project Portfolio Management (PPM) and Product Development solutions. This strategic acquisition further solidifies Planview's position as the undisputed leader in enterprise portfolio management, bringing market-leading solutions to organizations at every PPM maturity level. "By acquiring Sciforma, we're strengthening our commitment to portfolio management practitioners worldwide," said Razat Gaurav, CEO of Planview. "Together, we're building the world's largest community of portfolio and product development professionals, delivering enterprise solutions that address their most critical challenges. No one in the market is better equipped to guide organizations through every stage of their portfolio management evolution." This acquisition strengthens Planview's presence in Europe, where Scif

Armis Named a Leader in 2025 Gartner® Magic Quadrant ™ for CPS Protection Platforms18.2.2025 18:30:00 EET | Press release

Armis, the cyber exposure management & security company, today announced that it has been named a Leader in the 2025 Gartner Magic Quadrant for CPS Protection Platforms. Cyber-physical system environments connect the physical and digital worlds, supporting sectors including infrastructure, transportation, healthcare and smart manufacturing. Their growing role increases risk due to complex IT, OT, IoT, and IIoT integrations that need robust security. We believe the Gartner Magic Quadrant for CPS Protection Platforms highlights the importance of protecting these systems. “Attacks on cyber-physical systems can disrupt operations and endanger lives, making their security our core mission, driven by innovation, expertise and customer collaboration,” said Yevgeny Dibrov, CEO and Co-Founder of Armis. “We believe being named a Leader in this report is a testament to the support that we provide and the partnerships that we have with our customers as part of our unwavering commitment to redefini

Italian Tennis Star Jasmine Paolini Joins Amazfit as Latest Athlete Ambassador18.2.2025 17:00:00 EET | Press release

Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), today announced the signing of Italian tennis sensation and World No. 4 Jasmine Paolini as its newest global athlete partner. As part of the multi-year agreement and official smart wearable partnership, Paolini will represent Amazfit by wearing the Amazfit logo and smartwatch on court and the brand’s fitness wearables, including Helio Ring, to track sleep and athletic recovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218222601/en/ Italian Tennis Star Jasmine Paolini Joins Amazfit as Latest Athlete Ambassador (Photo: Business Wire) Paolini is the current Italian No. 1 and highest-ranked Italian singles player in WTA history. She reached both singles and doubles finals at the 2024 French Open and was a singles finalist at 2024 Wimbledon. Additionally, Paolini is the reigning Olympic gold medalist in doubles and holds two WTA singles an

G2 Risk Solutions Acquires ZignSec AB for More Holistic Risk Management18.2.2025 16:06:00 EET | Press release

G2 Risk Solutions (G2RS), a leading provider of risk management solutions in the financial sector, is announcing the acquisition of one of its affiliated companies of ZignSec AB (ZignSec). This marks a significant step forward in G2RS’ mission to deliver comprehensive, technology-driven compliance and risk solutions to regulated businesses worldwide. ZignSec AB provides cutting-edge identity verification solutions and owns Web Shield, a leader in merchant due diligence services, and Wyzer, a business process optimization and automation specialist. The collaboration among the three companies is expected to enable G2RS to enhance its portfolio of services and broaden its reach into critical areas of risk and compliance management globally. With this move, G2RS aims to strengthen its ability to serve highly regulated sectors, including financial institutions such as banks, lenders, creditors, merchant acquirers, supervisory entities, and internet platforms. “This is a pivotal moment for o

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye